Literature DB >> 26817316

Cardiometabolic risk in patients with polycystic ovary syndrome.

Katarzyna Ozegowska, Leszek Pawelczyk.   

Abstract

OBJECTIVES: Polycystic ovary syndrome (PCOS) is a common endocrinopathy in premenopausal women, associated with risk of metabolic syndrome and cardiovascular disease (CVD). CVD risk evaluation is recommended for PCOS patients. This study aimed to evaluate the risk of CVD in PCOS patients and to identify the best predictors for metabolic and cardiovascular disturbances.
MATERIAL AND METHODS: The study included 169 PCOS patients and 110 healthy women in reproductive age. We estimated cardiovascular risk according to American Heart Association and Androgen Excess-PCOS Society criteria that classified patients as metabolically unhealthy (MU) or metabolically healthy (MH).
RESULTS: The PCOS group had significantly higher body mass index (BMI), waist circumference, and waist-to-hip ratio (P < 0.000001). Metabolic syndrome was only defined among PCOS patients (8.9%). No obesity was observed in the control group. Waist circumference ≥ 80 cm was presented in 44% of PCOS patients in comparison to 14.5% of control participants (P < 0.000001). There was a significant tendency for higher fasting insulin levels in the PCOS population (P < 0.00001). Surprisingly the PCOS-MH group had the highest high-density lipoprotein (HDL) levels. ROC curves were used to indicate parameters diagnosing metabolically unhealthy women and revealed that WC, BMI and HC seem to be the strongest predictors of metabolic disturbances in PCOS but in the healthy population in reproductive age biochemical findings such as low HDL or increased fasting glycemia presented stronger predictive value than patients' anthropometric features.
CONCLUSIONS: Physicians need to remember to adopt different diagnostic approach while seeking metabolic complications in these different groups of women.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26817316     DOI: 10.17772/gp/59131

Source DB:  PubMed          Journal:  Ginekol Pol        ISSN: 0017-0011            Impact factor:   1.232


  4 in total

1.  Coronary artery disease risk in young women with polycystic ovary syndrome.

Authors:  Dah-Ching Ding; I-Ju Tsai; Jen-Hung Wang; Shinn-Zong Lin; Fung-Chang Sung
Journal:  Oncotarget       Date:  2018-01-04

2.  How much insulin resistance in polycystic ovary syndrome? Comparison of HOMA-IR and insulin resistance (Belfiore) index models.

Authors:  Krzysztof C Lewandowski; Elżbieta Skowrońska-Jóźwiak; Katarzyna Łukasiak; Katarzyna Gałuszko; Aleksandra Dukowicz; Magdalena Cedro; Andrzej Lewiński
Journal:  Arch Med Sci       Date:  2019-01-30       Impact factor: 3.318

3.  Heterogeneity of Endocrinologic and Metabolic Parameters in Reproductive Age Polycystic Ovary Syndrome (PCOS) Women Concerning the Severity of Hyperandrogenemia-A New Insight on Syndrome Pathogenesis.

Authors:  Katarzyna Ozegowska; Marcin Korman; Agnieszka Szmyt; Leszek Pawelczyk
Journal:  Int J Environ Res Public Health       Date:  2020-12-11       Impact factor: 3.390

4.  Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis.

Authors:  Luqian Zhao; Zhigang Zhu; Huiling Lou; Guodong Zhu; Weimin Huang; Shaogang Zhang; Feng Liu
Journal:  Oncotarget       Date:  2016-06-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.